Daniel de Castro

Dr. Daniel de Castro

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
AAAlmudena Amor-Salamanca
Almudena Amor-Salamanca
ARAlfredo Santana Rodríguez
Alfredo Santana Rodríguez
HRHazhee Rasoul
Hazhee Rasoul
JRJose Rodríguez-Palomares
Jose Rodríguez-Palomares
OMOana Moldovan
Oana Moldovan
JOJuan Pablo Ochoa
Juan Pablo Ochoa
BACKGROUND: Less than 40% of patients with dilated cardiomyopathy (DCM) have a pathogenic/likely pathogenic genetic variant identified. TBX20 has been linked to congenital heart defects; although an association with left ventricular noncompaction (LVNC) and DCM has been proposed, it is still considered a gene with limited evidence for these phenotypes. This study sought to investigate the association between the TBX20 truncating variant ( TBX20tv ) and DCM/LVNC. METHODS: TBX20 was sequenced by next-generation sequencing in 7463 unrelated probands with a diagnosis of DCM or LVNC, 22 773 probands of an internal comparison group (hypertrophic cardiomyopathy, channelopathies, or aortic diseases), and 124 098 external controls (individuals from the gnomAD database). Enrichment of TBX20tv in DCM/LVNC was calculated, cosegregation was determined in selected families, and clinical characteristics and outcomes were analyzed in carriers. RESULTS: TBX20tv was enriched in DCM/LVNC (24/7463; 0.32%) compared with internal (1/22 773; 0.004%) and external comparison groups (4/124 098; 0.003%), with odds ratios of 73.23 (95% CI, 9.90–541.45; P <0.0001) and 99.76 (95% CI, 34.60–287.62; P <0.0001), respectively. TBX20tv was cosegregated with DCM/LVNC phenotype in 21 families for a combined logarythm of the odds score of 4.53 (strong linkage). Among 57 individuals with TBX20tv (49.1% men; mean age, 35.9±20.8 years), 41 (71.9%) exhibited DCM/LVNC, of whom 14 (34.1%) had also congenital heart defects. After a median follow-up of 6.9 (95% CI, 25–75:3.6–14.5) years, 9.7% of patients with DCM/LVNC had end-stage heart failure events and 4.8% experienced malignant ventricular arrhythmias. CONCLUSIONS: TBX20tv is associated with DCM/LVNC; congenital heart defect is also present in around one-third of cases. TBX20tv -associated DCM/LVNC is characterized by a nonaggressive phenotype, with a low incidence of major cardiovascular events. TBX20 should be considered a definitive gene for DCM and LVNC and routinely included in genetic testing panels for these phenotypes.

23 July 2025 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
SLSara Lozano-Jiménez
Sara Lozano-Jiménez
CSCristina García Sebastian
Cristina García Sebastian
PMPaula Vela Martín
Paula Vela Martín
BMBelén García Magallón
Belén García Magallón
ACAlba Martín Centellas
Alba Martín Centellas
MRMercedes Rivas-Lasarte
Mercedes Rivas-Lasarte
Aims: Congestion is a major cause of hospitalisation in patients with heart failure (HF), and the persistence of congestive signs at discharge is a robust predictor of early readmission. Currently, there is increasing interest in the comprehensive assessment of subclinical congestion, as it can increase residual risk in individuals who appear to be euvolemic. Our aim was to investigate the prevalence and prognostic impact of subclinical venous congestion assessed by ultrasound. Methods and results: This is a two-centre, prospective observational study. Patients admitted for HF between June 2021 and March 2023 were selected. Clinical [physical examination (PE)] and subclinical venous congestion [Venous Excess Ultrasound score (VExUS)] were assessed. The prognostic impact was assessed through a composite endpoint of death from any cause, HF readmissions, or unscheduled visits requiring intravenous diuretic administration at 6-month follow-up. 120 patients were included (62% male, mean age 75 ± 15 years). Congestion parameters decreased during hospitalisation but tended to worsen at the first outpatient visit. At discharge, 24% showed subclinical venous congestion. This group had a significantly higher incidence of adverse outcomes, comparable to those with overt clinical congestion. Subclinical congestion was an independent predictor of the composite endpoint (HR 2.84; 95% CI: 1.01–8.01, P value = 0.048) after adjustment for age, chronic kidney disease, NYHA class at admission, and NT-proBNP level at discharge. Conclusion: Clinical and subclinical congestion decreased during hospitalisation but worsened shortly after discharge. A quarter of patients had residual venous congestion, which was associated with a worse prognosis at 6 months.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
PMP Vela Martin
P Vela Martin
CSCarlos Arellano Serrano
Carlos Arellano Serrano
VUV Castro Urda
V Castro Urda
DRD Garcia Rodriguez
D Garcia Rodriguez
FTF Hernandez Terciado
F Hernandez Terciado
JDJuan Francisco Oteo Domínguez
Juan Francisco Oteo Domínguez
Introduction: Permanent pacing is often needed in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) due to new onset conduction disorders. Nevertheless, continuous right ventricular pacing may deteriorate left ventricular ejection fraction (LVEF) and lead to poor outcomes. Thus, in last years, more physiological forms of pacing, such as left bundle branch pacing (LBBP) have been developed to prevent pacing induced cardiomyopathy. Purpose: The aim of our study is to describe the initial experience in our center, evaluate the safety and feasibility of LBBP after TAVI and describe electrophysiological outcomes in the first months of follow-up. Methods: We designed a prospective registry that collected all patients from the TAVI program of our center who developed conduction abnormalities in the immediate postoperative and received LBBP. We analyzed baseline characteristics, complications and procedure time, electrophysiological parameters after the procedure and final QRS interval. During follow-up LVEF, electrophysiological parameters and adverse clinical events (readmissions for heart failure, cardiovascular mortality and all-cause of mortality) were also evaluated at 3rd, 6th and 12th month. Results: Between January 2020 and January 2022, twenty patients who developed conduction abnormalities after TAVI underwent LBBP. Seven patients (35%) had a complete atrioventricular block, two patients (10%) alternating bundle branch block and 11 (55%) had a new left bundle branch block. HV electrophysiology study was performed in 8 patients, with a median value of 68ms (66–72). Of the 20 patients, 3 out of 4 patients were male and had history of hypertension. 40% had previous ischemic heart disease and one patient had transthyretin cardiac amyloidosis. Median age was 79 years-old (76–83.5). Balloon-expandable prosthesis was implanted in 11 patients while 9 received a self-expandable prosthesis. Median basal LVEF was 59% (41.5–60) and median NTproBNP was 1722pg/ml (535–5848). LBBP was successful in all of the 20 patients. The median time of the procedure was 60 minutes (45–80) without suffering any complications. The median QRS interval before the procedure was 155ms (140–158) and 116ms (105–125) post-implant. To date, two patients have died of non-cardiac cause 3 and 8 months after LBBP. There have been no readmissions for heart failure. LVEF (pre and post-LBBP) and electrophysiological parameters post-implant and three-month follow-up are shown in Table 1. Conclusions: In our experience, LBBP after TAVI is a safe and feasible procedure. Despite the small sample size and short follow-up period, our first results indicate stability of LVEF and pacemaker parameters. Funding Acknowledgement: Type of funding sources: None.

2 November 2022 in JACC: Case Reports
Verified
Journal Article
Open access
DCDaniel de Castro
Daniel de Castro
ARAlejandro Rasines-Rodríguez
Alejandro Rasines-Rodríguez
AUAna Usano
Ana Usano
SMSusana Mingo
Susana Mingo
A 16-year-old girl with a history of blunt chest trauma was admitted because of heart failure symptoms. Transthoracic echocardiography showed severe eccentric aortic regurgitation. Cardiac computed tomography revealed a pseudoaneurysm of the right sinus of Valsalva. We present a rare clinical presentation of a life-threatening condition. (Level of Difficulty: Intermediate.)

8 October 2024 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
DCDaniel de Castro
Daniel de Castro
DPDavid Pujol-Pocull
David Pujol-Pocull
FDFernando Domínguez
Fernando Domínguez
A 35-year-old man presented to the hospital with chest pain. He had a history of crystalline subluxation (Panel A), recurrent sprains, and bilateral inguinal hernia. Computed tomography angiography (Panels B and C) showed severe dilation of the ascending aorta (maximum diameter of 103 mm in axial plane) and ruled out dissection. An echocardiogram evidenced severe aortic regurgitation (see Supplementary data online, Video S1). The patient displayed facial dysmorphic features (Panel D) and lacked a family history of aortopathy or consanguinity. A Bentall procedure was performed successfully. Genetic testing (next-generation sequencing panel of 81 genes related to aortic diseases) did not detect any pathogenic variant, despite high suspicion of Marfan syndrome. Further trio-genome sequencing, including his parents, identified in the patient homozygosity (Panel E, arrow) for the c.1110_1112dup (p.Tyr371*) variant in the aspartate-β-hydroxylase gene (ASPH), confirming Traboulsi syndrome. Traboulsi syndrome1 is an autosomal recessive multisystem disorder characterized by features of connective tissue disorders, particularly those observed in Marfan syndrome, such as ectopia lentis, aortic dilatation, pectus excavatum, mitral valve prolapse, joint hypermobility, pes planus, or recurrent pneumothorax. Despite initial negative genetic testing, further advanced sequencing techniques were crucial in diagnosing this rare condition,2 highlighting the importance of comprehensive genetic evaluation in syndromic aortopathies.

29 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLSara Lozano-Jimenez
Sara Lozano-Jimenez
PMPaula Vela Martín
Paula Vela Martín
ACAlba Martin Centellas
Alba Martin Centellas
DCDaniel de Castro
Daniel de Castro
CMCristina Mitroi
Cristina Mitroi
MRMercedes Rivas-Lasarte
Mercedes Rivas-Lasarte
Background/Objectives: Congestion is a hallmark of heart failure (HF) and a major determinant of outcomes. Non-invasive tools enable detection of subclinical congestion, but their correlation and prognostic relevance remain incompletely defined. The present study aimed to assess the prevalence, evolution, interrelationships, and prognostic impact of clinical and subclinical congestion markers in patients hospitalized for HF. Methods: This single-centre, prospective cohort study included adults admitted with HF who underwent serial evaluations at admission, 72 h, pre-discharge, early outpatient follow-up and at 6 months. Clinical congestion was assessed using a standardized physical examination score. Subclinical congestion was evaluated using lung ultrasound (LUS), Venous Excess Ultrasound Score (VExUS), and Remote Dielectric Sensing (ReDS). Patients were classified according to the presence of clinical and/or subclinical congestion at discharge. The primary endpoint was a composite of all-cause mortality, HF readmission, or unscheduled visits requiring intravenous diuretics within six months. Results: Ninety-four patients (mean age 74 ± 11 years, 68% male) were included. While clinical congestion improved significantly during hospitalization, approximately 30% of patients remained clinically congested at discharge. Among clinically euvolemic patients, only 47% showed no evidence of subclinical congestion. Correlations between congestion markers were weak to moderate, suggesting complementary pathophysiological information. At discharge, pulmonary B-lines were the strongest predictor of the composite endpoint (hazard ratio [HR] 3.50, 95% CI 1.41–8.72), followed by clinical congestion (HR 2.67, 95% CI 1.13–6.30). Patients with clinical and subclinical congestion exhibited lower event-free survival. Conclusions: Subclinical congestion is common despite apparent clinical euvolemia and is associated with worse outcomes. Integrating clinical assessment with non-invasive congestion markers may improve post-discharge risk stratification in HF.